Trial Profile

An ambispective, observational, multicenter, 2-cohort real world study assessing the treatment patterns, patient-reported outcomes and healthcare resource utilization before and during Avelumab first-line maintenance in locally advanced/metastatic Urothelial carcinoma in the United States

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 29 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Jan 2024 According to a Merck & Co media release, data of this study will be presented at the 2024 American Society of Clinical Oncology's annual Genitourinary Cancers Symposium, January 25-27, in San Francisco.
18 Feb 2023 Results (n=77) assessing Response and outcomes of maintenance avelumab after platinum-based chemotherapy in patients with advanced urothelial carcinoma presented at the 2023 Genitourinary Cancers Symposium
18 Feb 2023 Results (n=160) presented at the 2023 Genitourinary Cancers Symposium

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com